BioSpace News Archive

Recognized healthcare and life science industry leader with over 35 years of international product development, strategy and commercialization experience

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Joe Mara, Chief Financial Officer, will present the latest company overview at the H.C. Wainwright Virtual Global Life Sciences Conference.

NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield urology therapy device has been added to the Federal Supply Schedule through a service disabled veteran organization,

Viveve Medical, Inc., a medical technology company focused on women’s intimate health, announced that Scott Durbin, chief executive officer, will participate in the virtual H.C. Wainwright Global Life Sciences Conference, March 9 - 10, 2021.

Owens & Minor, Inc. announced that it has launched a private offering of $500 million aggregate principal amount of senior notes due 2029, subject to customary and market conditions.

Sparta Group has signed a Memorandum of Understanding with Ethema Health Corporation of West Palm Beach, FL that could see the Company expand business into new markets related to the fight against emerging pathogens, including SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will participate in a fireside chat with ROTH Senior Research Analyst Elemer Piros, Ph.D. at the 33 rd Annual ROTH Conference, being held virtually March 15 – 17, 2021. 33 rd Annual ROTH Conference

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study.”

Emerging mutations to the coronavirus are unlikely to affect Brilacidin’s ability to inhibit the virus Brilacidin currently is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19 patients

Openness and transparency are key to building confidence in COVID-19 vaccines. Today, Health Canada and the European Medicines Agency (EMA) collaboratively published the full clinical data reviewed as part of their authorizations of the Moderna COVID-19 vaccine.